Custirsen + Placebo + Moxifloxacin

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 19/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cardiac Conduction and Repolarization

Conditions

Cardiac Conduction and Repolarization

Trial Timeline

May 1, 2013 → Jan 1, 2014

NCT ID

NCT01874561

About Custirsen + Placebo + Moxifloxacin

Custirsen + Placebo + Moxifloxacin is a phase 1 stage product being developed by Achieve Life Sciences for Cardiac Conduction and Repolarization. The current trial status is completed. This product is registered under clinical trial identifier NCT01874561. Target conditions include Cardiac Conduction and Repolarization.

What happened to similar drugs?

5 of 15 similar drugs in Cardiac Conduction and Repolarization were approved

Approved (5) Terminated (3) Active (8)

✅Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirinMerckApproved

✅Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + SteroidsNovartisApproved

✅Everolimus + Mycophenolate mofetil + EverolimusNovartisApproved

✅EpinephrinePfizerApproved

✅Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)Mochida PharmaceuticalApproved

🔄Edoxaban + Standard of Care (SOC)Daiichi SankyoPhase 3

🔄Everolimus (RAD001)NovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01874561	Phase 1	Completed	May 1, 2013	Jan 1, 2014	Cardiac Conduction and Repolarization

Competing Products

20 competing products in Cardiac Conduction and Repolarization

See all competitors

Product	Company	Stage	Hype Score
Edoxaban + Standard of Care (SOC)	Daiichi Sankyo	Phase 3	40
regadenoson	Astellas Pharma	Pre-clinical	26
Baricitinib (LY3009104) 4 mg	Eli Lilly	Phase 2	42
Current Domperidone + Current proton pump inhibitor (PPI)	Johnson & Johnson	Pre-clinical	26
Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin	Merck	Approved	35
Everolimus (RAD001)	Novartis	Phase 3	40
Deferasirox and Deferoxamine	Novartis	Phase 2	35
Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + Steroids	Novartis	Approved	43
TIN816	Novartis	Phase 2	27
Everolimus + Mycophenolate mofetil + Everolimus	Novartis	Approved	43
Pirfenidone + Placebo	Roche	Phase 2	35
Daclizumab	Roche	Phase 1/2	24
Ranolazine + Placebo	Gilead Sciences	Phase 3	32
Insulin infusion with a goal	Novo Nordisk	Phase 3	40
Epinephrine	Pfizer	Approved	50
sitaxsentan (Thelin) + sitaxsentan (Thelin) + Placebo	Pfizer	Phase 2	35
Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)	Mochida Pharmaceutical	Approved	43
BMS-986224	Bristol Myers Squibb	Phase 1	29
BMS-986231 + Furosemide + Placebo	Bristol Myers Squibb	Phase 2	35
Balinatunfib + Moxifloxacin + Placebo	Sanofi	Phase 1	36